This is a clinical trial for adult men with metastatic castrate resistant prostate cancer. The main purpose of this study is to evaluate the safety of the investigational drug Cabozantinib to see what its side effects are and if it works for this type of cancer.
   
Cabozantinib (Cometriq™, Cabometyx™) is an oral medication that blocks activity of specific proteins in the body. Cabozantinib is being experimentally tested for prostate cancer and is not yet approved by the United States Food and Drug Administration (FDA) as a standard of care option. Cabozantinib is FDA-approved for other forms of cancer.
   
All people participating in this study will be treated with cabozantinib and will continue to take luteinizing hormone-releasing hormone (LHRH) analogue therapy.
   
Participants will be in the study for approximately 12 months after enrollment. At that point, they will switch to long-term follow up for two years after completing the study.